Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
70%(7 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_2
5
38%
Ph phase_3
5
38%
Ph phase_4
3
23%

Phase Distribution

0

Early Stage

5

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Terminated(3)

Detailed Status

Completed10
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (38.5%)
Phase 35 (38.5%)
Phase 43 (23.1%)

Trials by Status

withdrawn18%
terminated215%
completed1077%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_3

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
completedphase_3

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

NCT00842348
completedphase_3

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708
terminatedphase_3

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
completedphase_2

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

NCT00326469
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00353496Phase 3

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Completed
NCT00842348Phase 3

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Completed
NCT00383708Phase 3

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Completed
NCT02683941Phase 3

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Terminated
NCT00326469Phase 2

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Completed
NCT00210457Phase 3

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Completed
NCT00681187Phase 4

Somatuline Autogel Preference and Health Economy Study

Completed
NCT02365584Phase 2

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Terminated
NCT00216398Phase 4

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Completed
NCT00149188Phase 4

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Completed
NCT00517491Phase 2

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Withdrawn
NCT00234572Phase 2

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Completed
NCT00891371Phase 2

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13